Philip Morris International (NYSE:PM) reported fourth-quarter earnings that beat Wall Street expectations, driven by double-digit growth in its smoke-free portfolio and the continued dominance of ZYN nicotine pouches in the U.S. market.
Pfizer (NYSE:PFE) officially debuted its discount program on the TrumpRx platform Thursday, offering more than 30 branded medicines at steep price cuts as part of its "Most Favored Nation" (MFN) pact with the White House.
BioArctic (NASDAQ:B) reported a sharp rise in royalty income for the final quarter of 2025, as the global rollout of its Alzheimer’s treatment Leqembi continues to gain traction across major markets.
Telehealth leader Hims & Hers Health (NYSE:HIMS) sent shockwaves through the pharmaceutical sector on Thursday, announcing the launch of a compounded oral semaglutide pill priced significantly lower than Novo Nordisk’s brand-name Wegovy.
Bristol Myers Squibb (NYSE:BMY) shares gained 4% on Thursday after the pharmaceutical giant reported fourth-quarter results that surpassed expectations, signaling that its "Growth Portfolio" is successfully absorbing the impact of patent expirations on legacy blockbusters.
Omnicell (NASDAQ:OMCL) reported a record top-line performance for the full year 2025 on Thursday, though shares faced pressure as fourth-quarter earnings fell short of Wall Street's expectations due to higher-than-anticipated operating costs.
Cardinal Health (NYSE:CAH) delivered a blowout second quarter on Thursday, significantly raising its full-year outlook as the drug wholesaler cashes in on robust demand for specialty therapeutics and high-margin GLP-1 medications.
Haemonetics (NYSE:HAE) posted third-quarter results on Thursday that cleared analyst estimates, proving that its aggressive move toward high-margin medical technologies is successfully offsetting the loss of legacy revenue streams.
Prestige Consumer Healthcare (NYSE:PBH) reported fiscal third-quarter results on Thursday that featured a revenue beat but an earnings miss, as the company worked to stabilize its supply chain for key brands like Clear Eyes® amid a "challenging consumer backdrop."
The Cigna Group (NYSE:CI) shares climbed on Thursday after the healthcare giant posted 2025 results that surpassed internal targets, fueled by explosive growth in its Evernorth health services division and a strategic pivot toward high-margin specialty pharmacy.
Alvotech (NASDAQ:ALVO) announced positive top-line results from a pivotal clinical study for its biosimilar candidate to Entyvio, positioning the Icelandic biotech to challenge one of the top-selling gastrointestinal treatments in a $6.4 billion market.
Natural Health Trends (NASDAQ:NHTC) signaled the near-completion of a major corporate overhaul even as it grappled with a 10% year-over-year revenue decline in its final quarter of 2025.
